Skip to content

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)

The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 1)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07303738
Enrollment
60
Registered
2025-12-26
Start date
2025-12-01
Completion date
2030-08-01
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspiration, Feeding Difficulties, Gastrostomy

Keywords

blenderized, bile acid, gastrostomy, aspiration

Brief summary

We will perform an acute physiology study comparing three different diets-an amino acid-based formula, a low bile acid-binding blenderized diet, or a high bile acid-binding blenderized diet administered through gastrostomy tube. We will determine the differences in gastric and salivary bile acid concentrations between participants over the 4 hour post-prandial timeframe. Participants who regularly receive an amino acid-based formula will receive an amino acid-based formula during the study and participants who regularly receive a blenderized feed will receive a blenderized feed during the study. Only participants who regularly receive blenderized feeds will be randomized to receive either the high or low bile acid binding blenderized feed.

Interventions

DRUGamino acid based formula (e.g. Elecare Jr)

We will administer one bolus of an amino acid based formula

DRUGlow bile acid binding blenderized diet (e.g. Kate Farms)

We will administer one bolus of a low bile acid binding blenderized diet

We will administer one bolus of a high bile acid binding blenderized diet

Sponsors

Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* receive at least 80% of their nutritional needs by gastrostomy * receive either an amino acid-based formula, an International Dysphagia Diet Standardization Initiative level 4 commercial blend, or a home blend * can receive bolus feeds of 240 cc within 30 minutes or less

Exclusion criteria

* have received a fundoplication * receive post-pyloric feeds * require medication/flush administration during the four-hour study period * are allergic to any component of the study diets. To participate in this study, if patients are taking acid suppression or motility medications (e.g., erythromycin, azithromycin, prucalopride), they will need to stop these at least 72 hours prior to participation in this aim.

Design outcomes

Primary

MeasureTime frameDescription
Gastric bile acid concentration4 hoursMean difference in gastric bile acid concentrations between start of feed and four hours following feed

Secondary

MeasureTime frameDescription
Gastric bile acid concentration1, 2 and 3 hoursDifferences in gastric bile acid concentrations from start of feed to 1, 2 and 3 hours after feed between groups
Correlations between gastric bile acid and gastroesophageal reflux Likert scaleBaseline to 1, 2, 3 and 4 hours post-prandialCorrelations between the postprandial changes in gastric bile acid concentrations and gastroesophageal reflux Likert scores
Correlation of symptom scores with gastric and salivary bile acid concentrationbaselinecomparison of PedsGIQL scores, GERD Likert scores, and PC-QoL scores with baseline gastric and salivary bile acid concentrations
Correlation of gastric and salivary bile acid concentrations0, 1, 2, 3 and 4 hours post-prandialcorrelations between gastric and salivary bile acid concentrations at each time point
correlations between C13 excretion rates and gastric and salivary bile acid concentrationsBaseline to 1, 2, 3 and 4 hours post-prandialcorrelations between C13 excretion rates and gastric and salivary bile acid concentrations

Countries

United States

Contacts

CONTACTRachel Rosen
rachel.rosen@childrens.harvard.edu617-355-0897

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 4, 2026